Fosamax (Alendronate) Safety in Adults 65 and Older

Why Geriatric Patients Need a Separate Safety Conversation

Adults over 65 face a fundamentally different pharmacological profile than younger patients starting alendronate. Kidney function declines at roughly 1 mL/min per year after age 40, polypharmacy burdens are higher, and the consequences of an esophageal injury or a fall-related fracture are more severe. At the same time, the absolute risk reduction from bisphosphonate therapy is actually larger in older patients because baseline fracture risk is higher, which means the number needed to treat (NNT) is lower.

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027 postmenopausal women with low bone density) showed alendronate reduced clinical vertebral fractures by 47% and hip fractures by 51% over three years in women with a prior vertebral fracture at baseline, the vast majority of whom were in their late 60s and 70s [1]. That trial remains the anchor evidence for geriatric prescribing decisions today.

Geriatric medicine organizations, including the American Geriatrics Society (AGS), have noted that bisphosphonates are among the more evidence-supported medications for older adults with confirmed osteoporosis, but that initiation and continuation decisions require individualized assessment of renal function, GI history, fall risk, and life expectancy [2].

Prescribers must run through at least four distinct safety checks before writing a first prescription for a patient over 65: creatinine clearance, GERD or esophageal motility history, current drug list for calcium or antacid interactions, and a fall risk screen. Each check is covered in detail below.

Renal Function: The First Gate

Alendronate is contraindicated when creatinine clearance (CrCl) falls below 35 mL/min, and this threshold catches a meaningful portion of older adults. The National Kidney Foundation estimates that roughly 37% of adults over 70 have CrCl values below 60 mL/min, and a subset will be below the 35 mL/min cutoff [3].

The mechanism matters here. Alendronate is not metabolized; it is cleared entirely by the kidney. In patients with reduced glomerular filtration, the drug accumulates in bone at higher concentrations than intended, raising theoretical concerns about adynamic bone disease, though clinical trial data below the 35 mL/min threshold are sparse precisely because those patients were excluded from FIT and similar trials.

The FDA label for alendronate sodium tablets specifies: "Alendronate is not recommended for patients with creatinine clearance <35 mL/min due to lack of experience with alendronate in renal failure" [4]. This language means the contraindication is a data gap, not necessarily a demonstrated harm, but clinical prudence supports following the label in the absence of trial evidence.

Practical recommendation: Obtain a basic metabolic panel or CMP before prescribing and use the CKD-EPI equation (not the Cockcroft-Gault equation alone) for a more accurate GFR estimate in patients with low muscle mass, which is common in older adults. Repeat CrCl annually. If function drops below 35 mL/min during therapy, stop alendronate and consult with nephrology or endocrinology about alternatives such as denosumab, which has no renal contraindication at standard doses.

Upper GI Tolerability: Esophageal and Gastric Risks

Alendronate causes direct mucosal injury when it contacts the esophageal or gastric wall. In the first post-marketing years, case reports of esophageal ulceration, bleeding, and stricture prompted the FDA to strengthen labeling. A 2010 FDA Drug Safety Communication noted an increased risk of esophageal cancer in patients taking oral bisphosphonates for more than five years, though subsequent large epidemiological studies have not confirmed a causal association definitively [5].

For older patients specifically, several physiological factors raise GI risk. Esophageal transit slows with age. Hiatal hernia prevalence exceeds 50% in adults over 70. Baseline rates of Barrett esophagus are higher. Many older patients also take NSAIDs or low-dose aspirin concurrently, compounding mucosal stress.

The mandatory administration instructions reduce but do not eliminate risk. Patients must swallow the tablet with a full glass (6-8 oz) of plain water, remain upright (sitting or standing) for at least 30 minutes, and take no other food or drink during that window. These requirements present a real adherence challenge for cognitively impaired patients or those with mobility limitations, both common in geriatric populations.

Absolute contraindications include esophageal abnormalities that delay emptying (achalasia, stricture), inability to stand or sit upright for 30 minutes, and hypocalcemia. For patients with a history of peptic ulcer disease or active GERD, clinical judgment should weigh the fracture risk reduction benefit against the GI risk, and proton pump inhibitor co-therapy is sometimes used, though it may modestly reduce alendronate absorption.

Drug-Drug Interactions Common in Older Adults

Polypharmacy is nearly universal by age 70. The average Medicare beneficiary takes between eight and ten prescription medications simultaneously. Several of those common medications interact directly with alendronate in ways that reduce efficacy or raise risk.

Calcium, antacids, and mineral supplements. Divalent cations bind alendronate in the gut, forming insoluble complexes that are not absorbed. Patients must take alendronate on an empty stomach, at least 30 minutes before any other oral medication, food, or drink. For patients on calcium carbonate three times a day (common in osteoporosis co-treatment), timing education is non-negotiable.

NSAIDs and aspirin. Both increase GI mucosal vulnerability. A 2006 cohort study published in the Archives of Internal Medicine (now JAMA Internal Medicine) found that concurrent NSAID use was associated with a roughly two-fold increase in upper GI adverse events in bisphosphonate users [6]. Prescribers should review the NSAID burden and consider substituting acetaminophen where possible.

Aminoglycosides. Concurrent use may lower serum calcium further, which is already a concern in older adults with borderline vitamin D status. Hypocalcemia must be corrected before starting alendronate; baseline 25-OH vitamin D should be above 20 ng/mL (preferably 30 ng/mL) and calcium intake should meet the National Osteoporosis Foundation target of 1,000-1 to 200 mg/day from diet and supplements combined [7].

Digoxin. Alendronate-induced hypocalcemia may increase the risk of digoxin toxicity. This interaction is pharmacodynamic rather than pharmacokinetic, but worth flagging given digoxin's continued use in older patients with heart failure or atrial fibrillation.

Falls and Fracture Risk: The Paradox of Bisphosphonate Use

Alendronate reduces fracture risk, but older patients taking it may still fall. Falls are the leading cause of fatal and non-fatal injury in adults over 65, and bisphosphonates do not prevent falls. The American Geriatrics Society Beers Criteria (2023 update) does not list bisphosphonates as potentially inappropriate medications for older adults, meaning they are not flagged as drugs to avoid based on age alone [2]. However, the AGS does recommend systematic fall risk assessment alongside any osteoporosis pharmacotherapy.

A practical consideration is that alendronate may cause musculoskeletal pain, including diffuse bone, joint, and muscle aching, sometimes severe enough to limit mobility and potentially worsen fall risk. The FDA updated labeling in 2008 to reflect this risk, citing post-marketing reports of severe and occasionally incapacitating musculoskeletal pain in bisphosphonate users [8]. The onset can be days to years after starting therapy. Prescribers should ask about new-onset pain at each follow-up and discontinue if the symptom profile fits.

Osteonecrosis of the Jaw (ONJ)

ONJ is characterized by exposed or necrotic bone in the maxillofacial region persisting for more than eight weeks in a patient taking an antiresorptive or antiangiogenic agent, without prior radiation therapy to the jaw. In older adult patients, the risk is directly linked to dose and duration of bisphosphonate exposure and to invasive dental procedures.

At the oral doses used for osteoporosis (70 mg weekly), the estimated incidence is 1 in 10,000 to 1 in 100,000 patient-treatment-years, far lower than in patients receiving intravenous bisphosphonates for cancer [9]. The American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper states that "the risk of ONJ in patients taking oral bisphosphonates for osteoporosis is very low and should not prevent patients from receiving necessary dental care" [9].

For geriatric patients, the clinical recommendation is a dental evaluation before starting therapy if the patient has not had a recent exam, address active dental disease before initiation where feasible, and advise the patient to inform any treating dentist about their bisphosphonate use. Drug holidays before elective dental procedures are sometimes practiced but not definitively supported by prospective data.

Atypical Femur Fractures: Duration-Dependent Risk

Atypical subtrochanteric and diaphyseal femur fractures (AFF) are low-energy fractures with a characteristic radiographic appearance: transverse or short oblique orientation, cortical thickening, and minimal comminution. They are associated with long-term bisphosphonate use and are thought to result from oversuppression of bone remodeling, which impairs the skeleton's ability to repair microdamage.

The absolute risk is low. A 2011 FDA Drug Safety Communication, based on a systematic review, estimated the incidence at approximately 1.78 per 100,000 person-years in patients with fewer than two years of bisphosphonate use, rising to 113.1 per 100,000 person-years with use of 8 years or more [10]. For context, alendronate prevents roughly 100 vertebral fractures per 100,000 patient-years in high-risk populations, so the net benefit remains positive through approximately 5 years for most patients.

In older patients who have taken alendronate for more than five years, the benefit-risk calculation becomes more nuanced. Prodromal thigh pain before AFF is present in many cases. Any patient on long-term bisphosphonate therapy who reports new anterior thigh or groin pain should have bilateral femur X-rays promptly.

Deprescribing: When to Stop or Pause Alendronate

The concept of a structured drug holiday is now a standard part of bisphosphonate management in older adults. The American Society for Bone and Mineral Research (ASBMR) task force and the Endocrine Society both provide guidance on this decision, though the evidence base is not as clean as prescribers might like.

The general framework used at HealthRX for geriatric patients follows four criteria evaluated at the five-year mark of oral bisphosphonate therapy:

1. Current fracture risk. Use FRAX (WHO fracture risk assessment tool) with femoral neck T-score input. If the 10-year hip fracture probability remains above 3% or the major osteoporotic fracture probability remains above 20%, continued therapy or transition to a different agent is generally preferred.

2. BMD trajectory. If T-score at the femoral neck remains below -2.5 at year five, continuing therapy or switching to a different class (denosumab, romosozumab, or anabolic therapy) is often appropriate. A T-score above -2.0 with no incident fractures during therapy supports a holiday.

3. Prior fractures. A patient who fractured a hip or vertebra while on therapy, or who had two or more prior fractures before starting, warrants a longer duration or alternative agent rather than a holiday.

4. Life expectancy and functional status. For patients with limited prognosis (less than 2-3 years) or severe frailty where the compound benefit of fracture prevention would not materialize within their expected lifespan, deprescribing is appropriate. The STOPP-Frail criteria (a validated tool for older adults in palliative care contexts) includes bisphosphonates among medications to consider stopping in patients with a prognosis of less than 1 year [11].

During a holiday, patients should continue calcium and vitamin D supplementation and return for DXA monitoring at two-year intervals. The holiday is not indefinite: if T-score declines by more than 0.03 g/cm2 per year at the hip, or if a new fracture occurs, restart therapy promptly.

Monitoring Protocol for Older Adults on Alendronate

Routine monitoring reduces the likelihood of missing emerging safety signals. The following schedule reflects guidance from the Endocrine Society's 2019 clinical practice guideline on osteoporosis pharmacotherapy [12]:

Before initiation. CrCl or eGFR; serum calcium, phosphate, and albumin; 25-OH vitamin D; dental review if indicated; fall risk screen (Timed Up and Go test or equivalent).

At 3 months. A brief phone or telehealth check for GI symptoms, musculoskeletal pain, and adherence to administration instructions. Studies suggest adherence to bisphosphonate once-weekly regimens drops below 50% within the first year in many older populations, and the fracture benefit disappears when adherence is poor [13].

Annually. Repeat eGFR, serum calcium, and vitamin D level. Review the drug list for new interactions.

At 3 years. DXA scan with vertebral fracture assessment (VFA) if not done recently. Reassess falls risk formally.

At 5 years. Full deprescribing review using the four-criteria framework above. If continuing, repeat DXA and FRAX.

Calcium and Vitamin D: Non-Negotiable Adjuncts

Alendronate will not work safely in a hypocalcemic patient. The drug suppresses bone resorption, and if dietary calcium is inadequate, parathyroid hormone rises to compensate, which blunts the BMD benefit. Hypocalcemia can also worsen in patients on alendronate without adequate vitamin D replacement.

The National Osteoporosis Foundation recommends 1 to 000 mg of calcium per day for men 50-70 and 1 to 200 mg/day for women over 50 and men over 70, from diet plus supplements combined [7]. For vitamin D, most osteoporosis guidelines recommend maintaining serum 25-OH vitamin D above 30 ng/mL, which typically requires 800-2 to 000 IU daily of cholecalciferol in older adults, particularly those with limited sun exposure or malabsorption.

Serum 25-OH vitamin D below 20 ng/mL is found in roughly 25% of community-dwelling older adults in northern latitudes [14]. Check it before starting alendronate and correct deficiency first.

Special Populations Within the Geriatric Group

Adults over 80. Evidence specifically from patients over 80 is limited because major trials enrolled relatively few of these individuals. However, post-hoc analyses of FIT and HORIZON (zoledronic acid) show fracture risk reduction in the oldest subgroups, supporting continued use in very old patients who are not frail and have preserved renal function. The FIRST study (Fracture Intervention Research Starting at Sixty-five) provides more targeted data for this age band [15].

Patients with cognitive impairment or dementia. Administration requires the patient to remain upright for 30 minutes and to take the medication correctly on an empty stomach. In patients with moderate-to-severe dementia, compliance with these requirements may be impossible without caregiver support. Weekly dosing (compared to daily) reduces the complexity burden, but prescribers should assess caregiver capacity explicitly. If safe administration cannot be assured, intravenous zoledronic acid once yearly is a practical alternative.

Post-hip fracture patients. Hip fracture in a patient over 65 is a sentinel event with a 20-30% one-year mortality. Initiating or continuing bisphosphonate therapy after surgical repair is supported by evidence and guidelines. A 2018 meta-analysis in the BMJ found that bisphosphonate therapy initiated within 90 days of hip fracture repair was associated with a 28% reduction in subsequent fracture risk and did not impair fracture healing [16].

Patients transitioning off denosumab. Denosumab discontinuation without a bridging bisphosphonate causes rapid bone loss and rebound vertebral fractures, a particularly dangerous scenario in older adults who may already have prevalent fractures. Sequential therapy with alendronate after denosumab cessation is the current standard of care, and the timing (typically alendronate starting 6 months after the last denosumab injection) should be coordinated carefully.

A Note on Adherence and Persistence

Poor adherence is the largest modifiable threat to alendronate effectiveness in older adults. A retrospective cohort analysis of over 38,000 Medicare beneficiaries found that only 44% of patients remained persistent with oral bisphosphonate therapy at 12 months, and non-adherent patients had a 45% higher fracture rate over three years compared to adherent patients [13]. Weekly regimens improve persistence compared to daily dosing, but they do not solve the problem.

Barriers specific to older patients include difficulty swallowing tablets, confusion about timing requirements, polypharmacy fatigue, and the absence of perceptible short-term benefit. Pharmacist counseling at initiation, clear written instructions in large print, and coordination with caregivers all improve adherence in geriatric practice.